



Mini-review

COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer

Richard J. Fagan^a, Andrew K. Dingwall^{a,b,*}^a Stritch School of Medicine, Loyola University Chicago, Maywood, IL, 60521, USA^b Department of Cancer Biology and Pathology & Laboratory Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, 60521, USA

ARTICLE INFO

Keywords:

Lysine methyltransferase
Chromatin
Epigenetic
Co-occurrence

ABSTRACT

The KMT2 (lysine methyltransferase) family of histone modifying proteins play essential roles in regulating developmental pathways, and mutations in the genes encoding these proteins have been strongly linked to many blood and solid tumor cancers. The KMT2A-D proteins are histone 3 lysine 4 (H3K4) methyltransferases embedded in large COMPASS-like complexes important for RNA Polymerase II-dependent transcription. *KMT2* mutations were initially associated with pediatric Mixed Lineage Leukemias (MLL) and found to be the result of rearrangements of the *MLL1/KMT2A* gene at 11q23. Over the past several years, large-scale tumor DNA sequencing studies have revealed the potential involvement of other KMT2 family genes, including heterozygous somatic mutations in the paralogous *MLL3/KMT2C* and *MLL2(4)/KMT2D* genes that are now among the most frequently associated with human cancer. Recent studies have provided a better understanding of the potential roles of disrupted KMT2C and KMT2D family proteins in cell growth aberrancy. These findings, together with an examination of cancer genomics databases provide new insights into the contribution of KMT2C/D proteins in epigenetic gene regulation and links to carcinogenesis.

1. Introduction

Post-translational histone modifications provide a vast epigenetic regulatory language that can be written and decoded by a large number of proteins and are important for controlling the timing and level of gene expression among all eucaryotes [1]. The methylation of lysine residues on N-terminal histone tails can provide both gene activation and repression signals and is one of the best-studied epigenetic modifications [2]. Methylation of histone 3 lysine 4 (H3K4) is frequently associated with active transcription, with di- and trimethylated H3K4 associated with active gene promoters and monomethylation found at gene enhancers [3]. The enzymes that place methyl modifications or marks on H3K4 are known as the KMT2 (lysine methyltransferase) family and are found embedded within enormous protein complexes, named COMPASS (COMplex of Proteins ASSociated with SET1) [4]. The discovery almost 30 years ago of recurrent translocation-associated leukemias involving *MLL1/KMT2A*, a homolog of the *Drosophila* Trithorax (Trx) protein important in *Hox* gene regulation, provided a critical platform for investigations into the roles of the KMT2 proteins in animal development and cancer [5–7]. More recently, genes encoding other KMT2 family proteins have been implicated in cancer [8]. Tumor genome and exome sequencing studies combined with cancer cell and

model system genetic analyses over the past decade have revealed an unanticipated vital role for the KMT2 family enzymes in a diverse set of cancers, both as drivers of oncogenesis and as critical cooperating mutations in both cancer progression and post-therapy relapse.

2. KMT2 COMPASS-like complexes

KMT2 family proteins (SET1A, SET1B, MLL1/KMT2A, MLL4(2)/KMT2B, MLL3/KMT2C and MLL2(4)/KMT2D) provide the histone lysine methyltransferase activity of mammalian COMPASS complexes. Designated MLL1-5 based on relatedness to the *MLL1* gene (Mixed Lineage Leukemia), KMT2 proteins comprise three subgroups, called COMPASS and COMPASS-like based homology with *Drosophila* Trx, Trr and dSet1 [4,8]. Genome duplication during mammalian evolution resulted in two paralogs in each KMT2 subgroup. KMT2A/MLL1 and KMT2B/MLL4(2) are paralogous proteins within the Trx related subgroup and we refer to this group as the MLX family (MLL-TRX). KMT2C and KMT2D are paralogous proteins within the Trr related subgroup that we refer to as the MLR family (MLL-TRR). KMT2F and KMT2G are paralogous proteins within the dSET1 subgroup (KMT2F and KMT2G will not be covered in this discussion) [5]. The COMPASS complexes are large, multi-subunit assemblies [4,9] that carry out mono-, di- and

* Corresponding author. Department of Cancer Biology, Loyola University Chicago-Stritch School of Medicine, Maywood, IL, 60153, USA.,
E-mail address: adingwall@luc.edu (A.K. Dingwall).




Fig. 1. Human COMPASS-like complexes and their histone targets. Two COMPASS-like families of complexes exist in higher eukaryotes, we indicate as MLX (MLL-TRX) and MLR (MLL-TRR) with distinct, though potentially limited overlapping target specificity. The MLX and MLR family complexes all contain catalytic subunits that methylate nucleosomes on histone 3 lysine 4 (H3K4) to produce di/trimethylation (H3K4me2/3; MLX family) or monomethylation (H3K4me1; MLR family). These histone modifications are associated with gene promoters and enhancers, respectively, and are linked to the activation of gene transcription. The MLX and MLR complexes both contain a set of core components (WDR5, RBBP5, ASH2 and hDPY30), as well as unique subunits. The MLX complexes contain Menin and HCF1 subunits, while the MLR complexes contain the histone lysine demethylase UTX, PTIP, PA1 and NCOA6.

trimethylation of histone 3 lysine 4 (H3K4). These modifications are placed on H3 N-terminal tails within nucleosomes at gene promoter and enhancer regions and are universally associated with transcription activation. The SET1A/B complexes perform the majority of di- and trimethylation of H3K4 throughout the genome [9]; whereas, the KMT2A/B (MLX) complexes are more limited in the targets of their enzymatic activities, primarily catalyzing di- and tri-methylation of H3K4 at gene promoters and nearby cis-regulatory sites where they maintain active transcription (Fig. 1). The KMT2C and KMT2D COMPASS-like (MLR) complexes monomethylate H3K4 (H3K4me1) at transcription enhancers throughout the human genome [10,11], with estimates ranging from approximately 12,000 to over 20,000 sites depending on cell type and developmental stage [12,13].

The MLR COMPASS complexes are recruited to enhancers through interactions with sequence specific transcription factors, including ligand-associated nuclear receptors and pioneer factors that activate enhancers *de novo*. Although nucleosomal H3K4me1 marking is important for establishing enhancer identity, full activation appears to require acetylation of H3K27 by the histone acetyltransferase p300/CBP, recruited to enhancers through direct interactions with the COMPASS-like complexes [12,14–16]. The presence of multiple methyl groups on H3K27, catalyzed by the Polycomb repressor PRC2 complex, can block the addition of the activating acetyl mark. In this case, the UTX/KDM6A lysine demethylase, a component of the MLR complexes, removes the methyl mark to allow for the addition of the acetyl group and subsequent enhancer activation. Through their epigenetic marking and commissioning of transcription enhancers, the MLR complexes contribute essential functions in developmental signaling [8,17,18].

KMT2A-D proteins are large (2715–5537aa) with multiple functional domains (see Fig. 2A). All contain plant homeodomain zinc finger structures (PHDf) that provide histone recognition and binding functions and interaction sites for other proteins. While the KMT2A/B proteins contain a single three PHD finger cluster within the N-terminal region and a single PHD finger near the C-terminus, the KMT2C/D proteins contain two closely related PHD finger clusters in the N-terminal regions (6–7 zinc-fingers) and a single PHD finger near the C-terminus. Each KMT2C/D cluster contains three to four zinc-coordinating PHD fingers in tandem. The first PHD cluster in KMT2C was recently shown to be involved in protein associations involving the BAP1 histone deubiquitinating repressor complex to control the expression of Polycomb-mediated transcriptional repression [13], while the highly conserved second cluster is thought to mediate direct chromatin interactions. A large number of cancer-associated missense mutations affecting the PHD finger clusters suggest these domains provide critical functions in controlling cellular growth and differentiation pathways through regulated binding to both modified histones and chromatin modifying complexes [13,19].

The histone modifying enzyme activity of the KMT2 family resides in the SET histone methyltransferase domain (KMTase; reviewed in Ref. [20]). The SET domain of the KMT2 family catalyzes the addition of methyl groups onto H3K4 residues that subsequently serve as markers for additional regulatory control. While the precise functional roles of methylated H3K4 in nucleosomes is uncertain, three key findings suggest that the H3K4me1 histone mark catalyzed by the MLR complexes is not essential for transcriptional regulation during development but is potentially important to control precise transcription levels or timing of gene transcription *in vivo*, perhaps critically in cancer. First, the histone methylation activity of the *Drosophila* Trr and murine Kmt2c/d proteins do not appear to be required for maintaining transcription activity after genes have been initially activated [21,22]. Second, both Kmt2c and Kmt2d are required for murine embryonic stem cell (mESC) differentiation, though not critical for self-renewal or maintenance of stem cell identity [12]. Third, while the SET methyltransferase activity of MLR complexes may be primarily important in the marking of enhancers, the SET domains are frequently mutated in cancers suggesting that they are responsible for chromatin modifications that broadly impact gene regulation. In support of this idea, there have been reported examples of SET domain cancer mutations in KMT2A and KMT2C that alter their enzymatic activity, in some cases increasing methylation activity while in other cases decreasing histone methylation [23,24], and truncations that specifically remove the SET domain in various tumors suggest that the methyltransferase activity may be important for cellular homeostasis. The discovery of both gain and loss of SET domain activity in cancer implies that there is considerable complexity in the potential mechanisms of oncogenesis associated with altered methyltransferase function. Additional protein domains of functional biological importance in the KMT2A/B family include AT-hooks, CXXC and bromodomains that are involved in DNA binding or protein-protein interactions. The AT-hooks bind to minor groove DNA and likely help to direct the KMT2 proteins to specific genomic regions [25] and deletion of the AT hooks can impair leukemic fusion protein functions [26]. The CXXC domain can distinguish epigenetically modified DNA (CpG methylation), as it only binds to unmethylated DNA, frequently found in active gene promoters. The CXXC domain is also involved in subnuclear localization and target gene selection of the KMT2A COMPASS complexes [27] and is reported to help recruit repressive factors, such as histone deacetylases (HDAC) and Polycomb group (PcG) complexes [27,28]. The AT hooks and CXXC domain are included in all KMT2A fusion associated leukemias and are thought to contribute to oncogenesis [26,27]. The KMT2C/D proteins contain an HMG domain that may provide similar DNA binding as the AT-hooks, and multiple nuclear receptor (NR) interaction motifs (LLXXL/LXXLL) that are important for recruitment of the complexes to NR-regulated enhancer targets [29,30]. However, it is unknown whether these




Fig. 2. Organization and mutation clustering of the KMT2A-D family proteins. A) The KMT2A-D proteins are enormous (2715-5265aa), and each contains multiple domains, including Plant Homeodomain (PHD), SET/Post-SET methyltransferase, FY-rich (FYR) regions, as well as domains that are specific for each member or family. The KMT2A/B proteins are cleaved post-translationally by the taspase protease; although, there is no known cleavage of the mature KMT2C/D proteins. The PHD domain cluster in KMT2A/B is highly related to the PHD ‘b’ domain cluster in KMT2C/D. The black diamonds represent putative nuclear receptor (NR) binding motifs (LLXXL, LXXLL). Data obtained from The Cancer Genome Atlas (TCGA) was used to map cancer associated mutations in each protein and to identify mutational hotspots by binning based on mutation type (missense/nonsense), suggesting important functional protein domains [13,31]. B) KMT2C and KMT2D are among the most frequently mutated cancer associated genes. Cancer mutation data was obtained from the NCI Genomic Data Commons Portal (GDC) that represents a summary of over 33,000 cases, including The Cancer Genome Atlas (TCGA) data. The top 20 most frequently mutated genes are shown together with the percent of cases affected across multiple cancer types.

domains in KMT2C/D play any direct role in cancer.

The establishment of several disease-associated mutation databases (e.g., TCGA, OMIM, COSMIC) has revealed that cancer-associated truncating/inactivating mutations are widely dispersed along the KMT2A-D proteins, confirming their importance as tumor suppressors (Fig. 2A). These databases also provide opportunities to gain insight into the potential biological significance of these domains in cancer. Missense mutation ‘hotspots’ are associated with known functional domains, including the PHD fingers, SET methyltransferase and regions associated with protein interactions [13,31]. As was recently shown for the KMT2C protein using MutClustSW, a recursive Smith-Waterman based algorithm [19], mutational hotspots are not randomly distributed, but strongly associated with the first PHD finger cluster and

with a second nearby region that has no identifiable domain. The first PHD finger cluster of KMT2C is involved in protein interactions with the BAP1 histone deubiquitinating complex and cancer associated mutations in this PHD domain disrupted recruitment of KMT2C to enhancers [13]. Alignment of the KMT2 proteins with mutation counts reveals additional ‘hotspots’ for missense mutations, supporting the existence of undiscovered functionally important domains that may be crucial for proper gene regulation.

3. Emerging roles for KMT2C and KMT2D in cancer

The epigenetic functions of the COMPASS complexes are vital for normal animal development and frequent mutations affecting these

proteins or other components of the COMPASS complexes are associated with a large number of cancers [32]. Mutations involving *KMT2* family genes are among the most commonly seen in many diverse cancer types and there is a statistically significant co-occurrence, raising the possibility that the simultaneous disabling of several *KMT2* genes might be a critical step in some cancer types. However, expression of *KMT2A* fusion oncoproteins can produce leukemias in the absence of additional *KMT2* mutations [33–35]. Similarly, murine knockout studies have shown that loss of *Kmt2d* can promote lymphomagenesis independent of additional mutations affecting other *KMT2* family genes [18,36]. Finally, a majority of cancers associated with *KMT2* family genes are the result of somatic heterozygous loss-of-function mutations, suggesting that haploinsufficiency may underlie disease for these epigenetic regulators [8].

As mentioned earlier, the majority of *KMT2A* associated cancers are the result of gene fusions producing leukemic oncoproteins, linking the N-terminal portion of *KMT2A* to over 135 different partner proteins, including 35 that are frequently recurring and nine partners that account for over 90% of *KMT2A*-based leukemias [37]. While the involvement of *KMT2A/MLL1* translocation fusions in cancer have been extensively reviewed [5,23,33,35,38], recent cancer exome sequencing studies have revealed a large number of missense (78%) and nonsense (22%) mutations in the gene with an overall somatic mutation frequency of 2.9%, suggesting possible loss and gain of function alterations of *KMT2A* in oncogenesis [23]. *KMT2B* is also found mutated in a variety of cancer types, with the majority (71%) being missense mutations and an overall somatic mutation frequency in cancer of 1.6%. Overexpression of *KMT2B* has also been observed in colorectal and breast cancer cell lines [39]. Although direct involvement in cancer is uncertain, *KMT2B* is important for maintaining promoter bivalency in embryonic stem cells [40] and it has been implicated in pediatric dystonia [41].

KMT2C and *KMT2D* were first linked to cancer through tumor sequencing studies showing frequent loss in pediatric and adult medulloblastoma [42,43], with *KMT2D* among the most highly mutated genes in Non-Hodgkin lymphoma [44,45]. More recently, the National Cancer Institute Genomic Data Commons (GDC) summary of over 33,000 cases revealed that *KMT2D* and *KMT2C* were the third and seventh most commonly mutated cancer genes (Fig. 2B). In addition, the cBio Portal database compendium [46,47] of almost 47,000 cancer samples representing 175 studies reveals that *KMT2D* and *KMT2C* are mutated in approximately 14–16% of all cases, with the highest percentages in both melanoma (27%) and non-melanoma (~48%) skin cancers, urothelial carcinoma (40%), bladder cancer (33%), lung cancer (18–26%), head and neck and esophagogastric cancers (19%), as well as colorectal and small bowel cancers (13.5%). Surprisingly, only in prostate cancer are both genes frequently amplified (13–19%), while *KMT2C* is amplified in approximately 5% of ovarian cancers. However, there is no obvious strong correlation between changes in the RNA levels of these genes and cancer phenotype, suggesting that loss-of-function mutations rather than expression level changes are generally associated with oncogenesis.

Haploinsufficiency of the human 7q chromosome region in acute myeloid leukemia implicated *KMT2C* as a likely tumor suppressor [48], and recent tumor sequencing data (TCGA-BRCA study) has revealed a strong enrichment for *KMT2C* mutations in breast cancer, with approximately 8% across breast cancer types and over 10% within invasive breast cancers according to the cBio Portal database, with substantially greater frequency than any other H3K4 methyltransferase. Importantly, *KMT2C* was recently shown to be important for driving hormone-stimulated cell proliferation in estrogen receptor alpha positive (ER α +) HER2-breast cancer cell lines but not ER α + HER2+ cells, while knockdown of *KMT2D* more broadly suppressed proliferation in breast cancer cells [49]. In this context, it appears that *KMT2C* is a critical co-factor in promoting ER α function and it appears to also have an important role in suppressing hormone-independent tumor

expansion. This dual role of *KMT2C* in breast cancer cell lines is consistent with patient data, in that *KMT2C* loss was more frequent (30%) in patients with metastatic hormone-refractory disease and they had a shorter progression-free survival following aromatase therapy [49]. In addition, Zhang et al. [50] developed a somatic mammary stem cell based mouse organoid model to identify functionally important genes involved in tumorigenesis. They found that murine *kmt2c* inactivation in cells overexpressing *Pik3ca* blocked mammary gland differentiation and simultaneously increased cell stem cell self renewal activity through activation of the HIF pathway. These studies suggest that *KMT2C* loss may be an important oncogenic driver that promotes increased stem cell-like properties, especially in ER α + breast cancers that also overexpress *PIK3CA*.

KMT2D is one of the most commonly mutated genes in both follicular lymphomas and diffuse large B cell lymphomas that arise from germinal center B cells with a mutation rate ranging from 35% to 85% [36,44,45]. The loss of *KMT2D* function appears to be an early co-operating event with overexpression of the *BCL2* oncogene to drive lymphomagenesis. Genetic ablation of murine *Kmt2d* in B cells promotes lymphoma development and impedes B cell differentiation, supporting its role as a tumor suppressor in germinal center B cells [18,36]. Conditional deletion of *Kmt2d* led to expansion of germinal center B-cells (GCB), while shRNA knockdown of *KMT2D* in human lymphoma cells was associated with increased proliferation *in vitro*, as well as decreased expression of tumor suppressor genes (e.g., *SOCS3*) that regulate B cell signaling pathways including JAK-STAT [18]. The loss of *KMT2D* results in reduced monomethylation marks at enhancers of multiple tumor suppressors which are known target genes of *KMT2D* [18,51–54]. Thus, *KMT2D* appears to function as a tumor suppressor in non-Hodgkin lymphoma by regulating genes required for B-cell development, as well as other cancer types through its function in enhancer activation.

4. Lessons from *KMT2C/D* mutations in lung cancer

Lung cancers, both non small cell (NSCLC, 85%) and small cell (SCLC, 15%), are a leading cause of cancer-associated deaths worldwide with few treatment options and a high recurrence rate. SCLC is a highly aggressive neuroendocrine tumor with a very poor prognosis in which *TP53* and *RB1* are frequently mutated. Several whole genome or exome sequencing studies have also revealed a high frequency of *KMT2D* (8–24%) but not *KMT2C* mutations [55–61]. These studies revealed that *KMT2D* is not only among the most frequently mutated genes in SCLC, but there is a strong bias for the loss of *KMT2D* via truncating mutations in the pathogenesis of SCLC with potentially significant prognostic impact [58].

Three subtypes of NSCLC include adenocarcinoma (LUAD), squamous cell carcinoma (LUSC) and large cell carcinoma (LCC). Meta analysis of 3065 samples covering 9 studies [62–67] shows *KMT2C/D* alterations in over 40% of squamous cell cancers of the lung, and up to 30% of adenocarcinoma of the lung. In both LUAD and LUSC, there is a trend towards significant co-occurrence of *KMT2C* and *KMT2D* mutations, with a log odds ratios of 0.861 and 0.837, respectively. While mutations account for the vast majority of alterations, amplifications are also observed. However, many of these cancers also have reduced *KMT2D* or *KMT2C* expression independent of mutation status and reduced expression was correlated with worse overall survival. A study from Yin et al. [68] identified deleterious *KMT2D* mutations in 12/105 NSCLC patients as well as reduced expression of *KMT2D* in tumors relative to paired adjacent non tumor tissues. This study also included whole exome sequencing of nine non small cell lung cancers and found that *KMT2D* was the second most significantly mutated gene after *TP53*, showing three missense mutations and two nonsense mutations in three out of nine samples. While all tumor samples showed reduced expression of *KMT2D* independent of mutation status, only *KMT2D* mutations were significantly associated with lower recurrence free survival.

Interestingly, many of the mutations in *KMT2D* resulted in silenced or significantly reduced expression in all of the sequenced tumor tissues compared with adjacent non-tumorous lung tissue. This study did not address the functional status of *KMT2C* in these mutated tissues, making it difficult to assess possible redundancy. A more recent analysis of 108 early stage (I-III) lung squamous cell carcinoma patients with matched normal tissue revealed *KMT2D* was mutated in 10.2% of lung tumors [69], consistent with TCGA data (178 patients) with a mutation frequency of 17.4%. In addition, it was found that patients with *KMT2D* mutations had a worse recurrence free survival, regardless of *TP53* status. Based on univariate analysis, *KMT2D* mutation status was the factor most strongly associated with poor prognosis [69]. Together, these findings indicate that *KMT2D* mutations also have a strong association with NSCLC pathogenesis. Again, functional status of *KMT2C* was not assessed in this study. As might be expected, many of the identified mutations in NSCLC affected genes involved with DNA damage checkpoint and cell cycle regulation. Choi et al. [69] found that among LUSC patients with *TP53* mutations, co-occurrence of *KMT2D* mutations was strongly correlated with poor recurrence free survival. An examination of the TCGA dataset for all NSCLC subtypes shows a significant co-occurrence between mutations in *TP53* and both *KMT2D* (odds ratio 0.763) and *KMT2C* (odds ratio 0.908) with adjusted *p*-values < 0.001 for both. A strong tendency of co-occurrence in lung squamous cell carcinomas and adenocarcinomas suggest that these three genes should be assessed in NSCLC tumors.

Expression levels of *KMT2C/D* genes have significant prognostic implications in some cancer types [70–73]. Significantly better survival rates are seen in adenocarcinoma of the lung with high expression levels of either *KMT2C* or *KMT2D* (Fig. 3A). However, this association is not seen in squamous cell carcinomas of the lung, with similar survival rates regardless of *KMT2C/D* expression levels (data not shown). Regardless of this difference, survival rates in all lung cancers are 20% higher at 10 years with high expression of *KMT2C* and *KMT2D* compared to low expression of both. The high rate of *KMT2D* mutations in these samples is suggestive that these alterations function as driver mutations, or mutations that are responsible for the development and progression of cancers. Data from the same meta analysis reveals that truncating mutations of *KMT2C* and *KMT2D* are present throughout all stages of the analyzed cancers, suggesting these mutations are present from early stages of cancer providing additional support for these alterations as driver mutations (Fig. 3B).

5. Functional distinctions between *KMT2C* and *KMT2D* in cancer

Possible oncogenic mechanisms associated with *KMT2C/D* loss involve the dysregulation of transcriptional enhancers and transcription factor-dependent programs that drive cellular pathways required for tumor suppression and anti-tumor immune evasion [12,21]. For example, several studies have demonstrated important direct interactions between *KMT2C/D* and the tumor suppressor *TP53* [74–78]. The activation of *TP53* target genes following doxorubicin (DNA damaging agent) treatment requires the coactivation functions of both *KMT2C* and *KMT2D* [77], and *KMT2D* enrichment sites overlap significantly with *TP53* genomic sites [79]. These studies reveal several potential mechanisms through which *KMT2C* and *KMT2D* cooperate with *TP53* in both transcription activation dependent and independent pathways to promote tumorigenesis. In human colon cancer cells harboring specific *TP53* mutations, there is aberrant gene activation that is dependent on *KMT2D* deposition of H3K4me1 marks on enhancers [74,78] providing a mechanistic explanation by which specific *TP53* gain of function mutations contribute to tumor formation. Intriguingly, *KMT2C* also appears to play an important role in cellular damage responses that rely on *TP53* function in maintaining genomic stability through DNA double strand break repair, a role that is independent of transcription activation [77].

Within early stage cancer cells, the *KMT2C/D* proteins help to

maintain epithelial cell states, such that loss may contribute to a more stem-cell like state and progression to metastasis. In gastric epithelial cells, the depletion of *KMT2C* is associated with a transition to a more mesenchymal phenotype, which can be reversed by adding back *KMT2C* [73]. Further, tumor-derived organoids depleted of *KMT2C* were more highly invasive in mouse xenografts. One possible mechanism may involve *KMT2C/D* interactions with cell-type specific transcription factors that drive mesenchymal-epithelial transition, such as GRHL2, that function to activate epithelial cell phenotypes and sensitize tumor cells to Natural Killer (NK) cell activity [80]. Simultaneous removal of both *KMT2C* (–/–) and *KMT2D* (±) in MCF10a cells converted them from an epithelial to a more mesenchymal morphology with reduced sensitivity to NK killing, suggesting an important role for these epigenetic modifiers in anti-tumor immunity [80].

The finding of *KMT2C* and *KMT2D* in essentially identical COMPASS complexes that catalyze mono-methylation of H3K4 at gene enhancers has raised the possibility that their functions were largely overlapping, such that loss of both might be important for oncogenesis [12,81]. Support for this theory can be seen through meta analysis of > 58,000 samples from the cBio Portal dataset that demonstrates significant tendency towards co-occurrence of *KMT2C* and *KMT2D* mutations with a log odds ratio of 1.65 (*p*-value < 0.001), perhaps indicating that loss of both proteins' tumor suppressor functions are important to confer malignant characteristics. However, the preponderance of mutations affecting only one of the two genes in specific cancer types suggests that each may have a critical role in cell-type or tissue-specific cancer development. The high frequency of *KMT2C* and *KMT2D* mutations, together with significant co-occurrence (*p* < 0.001) with various driver mutations (e.g., *TP53*, *PIK3CA*, *PTEN*, *APC*) and the SWI/SNF complex component *ARID1A* (log odds ratio 1.73, *p* = < 0.001) across multiple cancer types suggests that disruption of either *KMT2C* or *KMT2D* individually might serve as founder or gatekeeper mutations in early tumor cells, resulting in changes in the epigenomic landscape that are permissive for additional oncogenic changes.

Although mouse knockout studies reveal that *Kmt2c* can partially compensate for the absence of *Kmt2d* [81], both are essential genes which implies that each may have distinct functions in gene regulation. The mechanism(s) that distinguish *KMT2C* and *KMT2D* functions are not well understood as they share nearly identical domains and organization and presumably form identical MLR complexes [82]. One possible distinguishing difference is that *KMT2D* contains fewer zinc fingers within the first PHD domain cluster, possibly allowing for functional differences. Analysis of cancer-associated mutations reveals that there is a large clustering of lung and breast cancer missense mutations in the first *KMT2C* domain that are not found similarly in *KMT2D* [13]. This domain in *KMT2C* is involved in direct contacts with the BAP1 histone deubiquitinating complex that is linked to Polycomb-dependent gene silencing, suggesting that *KMT2C* may play a more critical role in cancers associated with Polycomb silenced gene enhancers [13]. Since *KMT2D* is lacking one of the conserved PHD finger domains and does not interact with the BAP1 protein, this difference may reflect how each protein is capable of distinct protein interactions that may account for differences in target gene regulation. Another difference is that *KMT2D* can be inactivated through phosphorylation by SGK1, a PI3K effector closely related to AKT1, and attenuate estrogen receptor (ER) activation in breast cancer cells [83,84]. Treatment of ER + breast cancers with a PI3K inhibitor is effective clinically, but also results in increased ER-dependent transcription that can result in therapeutic resistance [85]. ER activates its targets through interaction with *KMT2D* at enhancers. One of those targets is the estrogen inducible kinase SGK1, whose expression is induced upon inhibition of PI3K. Subsequently, SGK1 can inactivate *KMT2D* through phosphorylation at S1331 near the second PHD finger cluster implicated in chromatin binding and result in downregulation of global H3K4me1 levels at ER-regulated loci, as part of a negative feedback loop [83].




Fig. 3. KMT2C/D involvement in lung cancer development and survival. A) K-M plotter analysis of the correlation between *KMT2C* and *KMT2D* transcript expression and survival probability among lung adenocarcinoma patients. Low expression of both genes is correlated with shorter overall survival time. B) Association of *KMT2C* and *KMT2D* mutations with lung cancer type, stage of first detection and overall patient survival. Data was obtained from the cBio Portal, analyzing 1144 patients with lung adenocarcinoma or squamous cell carcinoma. Staging is according to the American Joint Committee on Cancer (AJCC). Truncating mutations of *KMT2D* are commonly observed in early stage lung squamous cell carcinomas, suggesting driver function; whereas, missense mutations in *KMT2C* are common in early stage lung adenocarcinomas.

Although the mechanism is unknown, targeted phosphorylation and inactivation of *KMT2D* by both *SGK1* and/or *AKT1* can lead to down-regulation of enhancers controlled by *KMT2D*-associated transcription factors. Notably, *KMT2C* does not contain the AGC kinase consensus sequence (RXRXXS/T) in a similar position relative to the PHD finger cluster. The distinctions between the *KMT2C* and *KMT2D* proteins are unlikely to be limited to these differences, but probably include varied protein interactions and differential chromatin targeting.

6. Germline roles of *KMT2*-family genes in cancer predisposition

The *KMT2A-D* genes are each essential for organismal viability, with strong depletion, homozygous loss of function mutations or deletions resulting in embryonic or perinatal lethality (*KMT2A/MLL1*: [86,87]; *KMT2B/MLL4(2)*: [88]; *KMT2C/MLL3* and *KMT2D/MLL2(4)*: [81,89]). Somatic mutations in the *KMT2A-D* genes have been strongly linked to cancer development; however, it is less clear the impacts of *de novo* germline mutations in cancer predisposition. The *KMT2A-D* genes have each been associated with developmental disorders, with common phenotypic features that include intellectual disability and often

skeletal abnormalities. Germline heterozygous mutations in *KMT2A* are associated with Weidemann-Steiner syndrome [90,91] and rarely, pediatric eosinophilia [92]. Inactivating mutations of *KMT2B* that include microdeletions and pathogenic variants have been linked to pediatric dystonia, a hyperkinetic movement disorder [41,93,94]. Heterozygous germline loss of *KMT2C* is associated with autism spectrum disorder and Kleefstra syndrome, a developmental disorder associated with skeletal and intellectual defects [95,96]. Heterozygous mutations in human *KMT2D* are also frequently associated with developmental anomalies and malignancy. Inactivating germline mutations in *KMT2D* are strongly correlated (55–80%) with Kabuki Syndrome, a developmental disorder characterized by distinct facial features, mild to severe developmental delay and intellectual disability, skeletal defects and cardiac abnormalities [97].

Cancer predisposition is not a significant feature of *KMT2A/B/C* germline mutations. Although translocation fusions of *KMT2A* with a variety of partner proteins are directly linked to pediatric leukemias [33,35], there is no clear link between germline loss of *KMT2A* function and oncogenesis. In contrast, heterozygous germline inactivating mutations in *KMT2D* have been linked to several cancers. The *de novo*

mutations are inherited in an autosomal dominant pattern and Kabuki syndrome patients have a modest predisposition to cancer, including lymphoma, Wilms tumor (kidney), hepatoblastoma (liver), synovial sarcoma (lung) and neuroblastoma [98]. Brain-specific knockout of *Kmt2d* in mice is associated with spontaneous medulloblastoma, perhaps through hyperactivation of the Ras and Notch pathways and down-regulation of tumor suppressor genes [99]. In light of the significant role of somatic loss of *KMT2C/D* in multiple cancer types, the relative lack of pediatric cancers associated with *KMT2A/B/C* suggest that heterozygous inactivation of these genes is insufficient to drive epigenetic changes associated with tumor formation and likely require additional cooperating mutations for cancer development. However, reduced *KMT2D* germline function is associated with several pediatric cancers, perhaps allowing for epigenetic changes that in combination with other driver mutations, leads to aberrant growth [100,101] through the misregulation of critical signaling pathways controlled by *KMT2D*.

During embryonic development, *KMT2D* and *KMT2C* have important roles in enhancer priming and *de novo* enhancer activation; thus, loss of these activities in early animal development may lead to an inability to appropriately activate critical developmental signaling pathways important for controlling growth and differentiation [79]. These functions appear to be dispensable for maintaining cell identity and self-renewal in both murine embryonic stem cells (ESCs) and somatic cells, but essential for reprogramming ESCs during differentiation and for generating induced pluripotent stem cells (iPSCs) [12]. Murine ESCs expressing *KMT2D* were able to form cystic embryoid bodies consisting of all three germ layers, while those with *KMT2D* deleted only formed poorly differentiated primitive stem cells. Somatic cells manipulated to induce the formation of pluripotent stem cells (iPSC) were able to form embryonic stem cell like colonies when *KMT2D* was present; whereas, cells with *KMT2D* deleted showed a dramatic decrease in reprogramming efficiency and showed a decreased expression of pluripotency markers. These results reveal a critical role of *KMT2C/D* COMPASS complexes in establishing pluripotent cell identity during somatic reprogramming, thus suggesting a role for loss of *KMT2C/D* function in aberrant growth and differentiation.

7. Conclusions and perspectives

Cancer exome databases reveal that the *KMT2C/MLL3* and *KMT2D/MLL2(4)* histone lysine methyltransferases are among the most frequently mutated genes across a variety of cancer types. Most of these cancers are associated with mutations that alter the proteins through missense changes or truncations resulting in reduced functions, supporting their roles as tumor suppressors. Genetic removal of these genes in cancer cells, embryonic stem cells, as well as both vertebrate and invertebrate animal models has confirmed their requirement as transcription enhancer regulators.

While it is difficult to therapeutically target loss-of-function tumor suppressors directly, recent work has shown there is promise for targeting repressor enzymes, such as EZH2 that places a trimethyl mark on histone 3 lysine 27 (H3K27) which serves to block some enhancer activities [13]. Inhibitors that block the activities of EZH2, such as GSK126, result in the restoration of gene expression in *KMT2C* mutant cells. A recently discovered role for *KMT2C* in homology-driven DNA repair and genomic instability in bladder cancer cells has opened the possibility that some *KMT2C*-associated cancers may be targeted by PARP1/2 inhibitors [102]. Another potential target of inhibition is the COMPASS-like complex subunit WDR5, found in all COMPASS complexes. A report by Senisterra et al. [103] identified a compound that would inhibit WDR5 interaction with MLL1/*KMT2A* and histone H3, reducing histone methyltransferase activity and H3 binding *in vitro*. Whether this compound would disrupt WDR5 interactions with *KMT2C/D* remains to be determined. The loss of *kmt2d* in a zebrafish model of Kabuki syndrome results in hyperactivation of MEK within the

RAS/MAPK pathway and treatment with the BRAF inhibitor desmethyl dabrafenib (dmDf) can rescue the Kabuki-like phenotypes [104]. Dabrafenib has shown clinical efficacy in treating tumors (especially melanoma) with BRAF hyperactivation mutations; thus, tumors with *KMT2D* mutations may be candidates for treatment with MAPK pathway inhibitors.

Author contributions

AD and RF conceived the idea for the review, researched the literature and wrote the manuscript.

Conflict of interest statement

The authors declare that they have no competing financial interests.

Acknowledgements

We thank Claudia Zraly, David Ford and Matthew Kroll for helpful advice and comments on the manuscript. R. F. was supported by a NIH T35 award from the NHLBI (HL120835). The research in the laboratory of A.D. is supported by the National Science Foundation (MCB1716431).

References

- [1] S.B. Rothbart, B.D. Strahl, Interpreting the language of histone and DNA modifications, *Biochim. Biophys. Acta* 1839 (2014) 627–643.
- [2] E.L. Greer, Y. Shi, Histone methylation: a dynamic mark in health, disease and inheritance, *Nat. Rev. Genet.* 13 (2012) 343–357.
- [3] E. Calo, J. Wysocka, Modification of enhancer chromatin: what, how, and why? *Mol. Cell* 49 (2013) 825–837.
- [4] A. Shilatifard, The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis, *Annu. Rev. Biochem.* 81 (2012) 65–95.
- [5] R.C. Rao, Y. Dou, Hijacked in cancer: the KMT2 (MLL) family of methyltransferases, *Nat. Rev. Canc.* 15 (2015) 334–346.
- [6] R.K. Slany, When epigenetics kills: MLL fusion proteins in leukemia, *Hematol. Oncol.* 23 (2005) 1–9.
- [7] R.K. Slany, The molecular mechanics of mixed lineage leukemia, *Oncogene* 35 (2016) 5215–5223.
- [8] D.J. Ford, A.K. Dingwall, The cancer COMPASS: navigating the functions of MLL complexes in cancer, *Cancer Genet* 208 (2015) 178–191.
- [9] M. Mohan, H.M. Herz, E.R. Smith, Y. Zhang, J. Jackson, M.P. Washburn, L. Florens, J.C. Eissenberg, A. Shilatifard, The COMPASS family of H3K4 methylases in *Drosophila*, *Mol. Cell. Biol.* 31 (2011) 4310–4318.
- [10] D. Hu, X. Gao, M.A. Morgan, H.M. Herz, E.R. Smith, A. Shilatifard, The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 mono-methylases at enhancers, *Mol. Cell. Biol.* 33 (2013) 4745–4754.
- [11] A. Pianti, A. Shilatifard, Epigenetic balance of gene expression by Polycomb and COMPASS families, *Science* 352 (2016) aad9780.
- [12] C. Wang, J.E. Lee, B. Lai, T.S. Macfarlan, S. Xu, L. Zhuang, C. Liu, W. Peng, K. Ge, Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition, *Proc. Natl. Acad. Sci. U. S. A.* 113 (2016) 11871–11876.
- [13] L. Wang, Z. Zhao, P.A. Ozark, D. Fantini, S.A. Marshall, E.J. Rendleman, K.A. Cozzolino, N. Louis, X. He, M.A. Morgan, Y.H. Takahashi, C.K. Collings, E.R. Smith, P. Ntziachristos, J.N. Savas, L. Zou, R. Hashizume, J.J. Meeks, A. Shilatifard, Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy, *Nat. Med.* 24 (2018) 758–769.
- [14] B. Lai, J.E. Lee, Y. Jang, L. Wang, W. Peng, K. Ge, MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis, *Nucleic Acids Res.* 45 (2017) 6388–6403.
- [15] S.P. Wang, Z. Tang, C.W. Chen, M. Shimada, R.P. Koche, L.H. Wang, T. Nakadai, A. Chromiec, A.V. Krivtsov, S.A. Armstrong, R.G. Roeder, A UTX-MLL4-p300 transcriptional regulatory network coordinately shapes active enhancer landscapes for eliciting transcription, *Mol. Cell* 67 (2017) 308–321 e306.
- [16] F. Tie, R. Banerjee, P.A. Conrad, P.C. Scacheri, P.J. Harte, Histone demethylase UTX and chromatin remodeler BRM bind directly to CBP and modulate acetylation of histone H3 lysine 27, *Mol. Cell. Biol.* 32 (2012) 2323–2334.
- [17] R. Baas, H. van Teeffelen, S.J.D. Tjalsma, H.T.M. Timmers, The mixed lineage leukemia 4 (MLL4) methyltransferase complex is involved in transforming growth factor beta (TGF-beta)-activated gene transcription, *Transcription* 9 (2018) 67–74.
- [18] A. Ortega-Molina, I.W. Boss, A. Canela, H. Pan, Y. Jiang, C. Zhao, M. Jiang, D. Hu, X. Agirre, I. Niesvizky, J.E. Lee, H.T. Chen, D. Ennishi, D.W. Scott, A. Mottok, C. Hother, S. Liu, X.J. Cao, W. Tam, R. Shaknovich, B.A. Garcia, R.D. Gascoyne, K. Ge, A. Shilatifard, O. Elemento, A. Nussenzweig, A.M. Melnick, H.G. Wendel, The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development, *Nat. Med.* 21 (2015) 1199–1208.

- [19] J.K. Rhee, J. Yoo, K.R. Kim, J. Kim, Y.J. Lee, B.C. Cho, T.M. Kim, Identification of local clusters of mutation hotspots in cancer-related genes and their biological relevance, *IEEE ACM Trans. Comput. Biol. Bioinform* (2018), <https://doi.org/10.1109/TCBB.2018.2813375>.
- [20] C. Qian, M.M. Zhou, SET domain protein lysine methyltransferases: structure, specificity and catalysis, *Cell. Mol. Life Sci.* 63 (2006) 2755–2763.
- [21] K.M. Dorighi, T. Swigut, T. Henriques, N.V. Bhanu, B.S. Scruggs, N. Nady, C.D. Still 2nd, B.A. Garcia, K. Adelman, J. Wysocka, MLL3 and MLL4 facilitate enhancer RNA synthesis and transcription from promoters independently of H3K4 monomethylation, *Mol. Cell* 66 (2017) 568–576 e564.
- [22] R. Rickels, H.M. Herz, C.C. Sze, K. Cao, M.A. Morgan, C.K. Collings, M. Gause, Y.H. Takahashi, L. Wang, E.J. Rendleman, S.A. Marshall, A. Krueger, E.T. Bartom, A. Piunti, E.R. Smith, N.A. Abshiru, N.L. Kelleher, D. Dorsett, A. Shilatifard, Histone H3K4 monomethylation catalyzed by Trx and mammalian COMPASS-like proteins at enhancers is dispensable for development and viability, *Nat. Genet.* 49 (2017) 1647–1653.
- [23] S. Weirich, S. Kudithipudi, A. Jeltsch, Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex, *Mol Oncol* 11 (2017) 373–387.
- [24] S. Weirich, S. Kudithipudi, I. Kycia, A. Jeltsch, Somatic cancer mutations in the MLL3-SET domain alter the catalytic properties of the enzyme, *Clin. Epigenet.* 7 (2015) 36.
- [25] N.J. Zeleznik-Le, A.M. Harden, J.D. Rowley, 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene, *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994) 10610–10614.
- [26] R.K. Slany, C. Lavau, M.L. Cleary, The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX, *Mol. Cell. Biol.* 18 (1998) 122–129.
- [27] C. Bach, D. Mueller, S. Buhl, M.P. Garcia-Cuellar, R.K. Slany, Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2, *Oncogene* 28 (2009) 815–823.
- [28] Z.B. Xia, M. Anderson, M.O. Diaz, N.J. Zeleznik-Le, MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 8342–8347.
- [29] Y. Sedkov, E. Cho, S. Petruk, L. Cherbas, S.T. Smith, R.S. Jones, P. Cherbas, E. Cavanaugh, J.B. Jaynes, A. Mazo, Methylation at lysine 4 of histone H3 in ecdysone-dependent development of *Drosophila*, *Nature* 426 (2003) 78–83.
- [30] E. Froimchuk, Y. Jang, K. Ge, Histone H3 lysine 4 methyltransferase KMT2D, *Gene* 627 (2017) 337–342.
- [31] D. Fantini, A.P. Glaser, K.J. Rimar, Y. Wang, M. Schipma, N. Varghese, A. Rademaker, A. Behdad, A. Yellapa, Y. Yu, C.C. Sze, L. Wang, Z. Zhao, S.E. Crawford, D. Hu, J.D. Licht, C.K. Collings, E. Bartom, D. Theodorou, A. Shilatifard, J.J. Meeks, A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer, *Oncogene* 37 (2018) 1911–1925.
- [32] H.M. Herz, D. Hu, A. Shilatifard, Enhancer malfunction in cancer, *Mol. Cell* 53 (2014) 859–866.
- [33] W. Yang, P. Ernst, Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis, *Curr. Opin. Hematol.* 24 (2017) 322–328.
- [34] A.V. Krivtsov, S.A. Armstrong, MLL translocations, histone modifications and leukaemia stem-cell development, *Nat. Rev. Canc.* 7 (2007) 823–833.
- [35] A.V. Krivtsov, T. Hoshii, S.A. Armstrong, Mixed-Lineage leukemia fusions and chromatin in leukemia, *Cold Spring Harb Perspect Med* 7 (2017).
- [36] J. Zhang, D. Dominguez-Sola, S. Hussein, J.E. Lee, A.B. Holmes, M. Bansal, S. Vlassevska, T. Mo, H. Tang, K. Basso, K. Ge, R. Dalla-Favera, L. Pasqualucci, Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis, *Nat. Med.* 21 (2015) 1190–1198.
- [37] C. Meyer, T. Burmeister, D. Groger, G. Tsaur, L. Fechina, A. Renneville, R. Sutton, N.C. Venn, M. Emerenciano, M.S. Pombo-de-Oliveira, C. Barbieri Blunck, B. Almeida Lopes, J. Zuna, J. Trka, P. Ballerini, H. Lapillonne, M. De Braekeleer, G. Cazzaniga, L. Corral Abascal, V.H.J. van der Velden, E. Delabesse, T.S. Park, S.H. Oh, M.L.M. Silva, T. Lund-Aho, V. Juvonen, A.S. Moore, O. Heidenreich, J. Vormoor, E. Zerkalenkova, Y. Olshanskaya, C. Bueno, P. Menendez, A. Teigler-Schlegel, U. Zur Stadt, J. Lentjes, G. Gohring, A. Kustanovich, O. Aleinikova, B.W. Schafer, S. Kubetzko, H.O. Madsen, B. Gruhn, X. Duarte, P. Gameiro, E. Lippert, A. Bidet, J.M. Cayuela, E. Clappier, C.N. Alonso, C.M. Zwaan, M.M. van den Heuvel-Eibrink, S. Izraeli, L. Trakhtenbrot, P. Archer, J. Hancock, A. Moricke, J. Alten, M. Schrappe, M. Stanulla, S. Strehl, A. Attarbaschi, M. Dworak, O.A. Haas, R. Panzer-Grumayer, L. Sedek, T. Szczepanski, A. Caye, L. Suarez, H. Cave, R. Marschalek, The MLL recombinome of acute leukemias in 2017, *Leukemia* 32 (2018) 273–284.
- [38] A.C. Winters, K.M. Bernt, MLL-rearranged leukemias—an update on science and clinical approaches, *Front Pediatr* 5 (2017) 4.
- [39] T.G. Natarajan, B.V. Kallakury, C.E. Sheehan, M.B. Bartlett, N. Ganesan, A. Preet, J.S. Ross, K.T. Fitzgerald, Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon, *Cancer Cell Int.* 10 (2010) 13.
- [40] G. Mas, E. Blanco, C. Ballare, M. Sanso, Y.G. Spill, D. Hu, Y. Aoi, F. Le Dily, A. Shilatifard, M.A. Marti-Renom, L. Di Croce, Promoter bivalency favors an open chromatin architecture in embryonic stem cells, *Nat. Genet.* 50 (2018) 1452–1462.
- [41] E. Meyer, K.J. Carss, J. Rankin, J.M. Nichols, D. Grozeva, A.P. Joseph, M.E. Mencacci, A. Papandreou, J. Ng, S. Barral, A. Ngho, H. Ben-Pazi, M.A. Willemssen, D. Arkadir, A. Barnicoat, H. Bergman, S. Bhatte, A. Boys, N. Darin, N. Foulds, N. Gutowski, A. Hills, H. Houlden, J.A. Hurst, Z. Israel, M. Kaminska, P. Limousin, D. Lumsden, S. McKee, S. Misra, S.S. Mohammed, V. Nakou, J. Nicolai, M. Nilsson, H. Pall, K.J. Peall, G.B. Peters, P. Prabhakar, M.S. Reuter, P. Rump, R. Segel, M. Sinnema, M. Smith, P. Turnpenny, S.M. White, D. Wiczorek, S. Wiethoff, B.T. Wilson, G. Winter, C. Wragg, S. Pope, S.J. Heales, D. Mirogoh, U.K. Consortium, S. Deciphering Developmental Disorders, N.B.R.D. Consortium, A. Pittman, L.J. Carr, B. Perez-Duenas, J.P. Lin, A. Reis, W.A. Gahl, C. Toro, K.P. Bhatia, N.W. Wood, E.J. Kamsteeg, W.K. Chong, P. Gissen, M. Topf, R.C. Dale, J.R. Chubb, F.L. Raymond, M.A. Kurian, Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia, *Nat. Genet.* 49 (2017) 223–237.
- [42] D.W. Parsons, M. Li, X. Zhang, S. Jones, R.J. Leary, J.C. Lin, S.M. Boca, H. Carter, J. Samayoa, C. Bettegowda, G.L. Gallia, G.I. Jallo, Z.A. Binder, Y. Nikolsky, J. Hartigan, D.R. Smith, D.S. Gerhard, D.W. Fults, S. Vandenberg, M.S. Berger, S.K. Marie, S.M. Shinjo, C. Clara, P.C. Phillips, J.E. Minturn, J.A. Biegel, A.R. Judkins, A.C. Resnick, P.B. Storm, T. Curran, Y. He, B.A. Rasheed, H.S. Friedman, S.T. Keir, R. McLendon, P.A. Northcott, M.D. Taylor, P.C. Burger, G.J. Riggins, R. Karchin, G. Parmigiani, D.D. Bigner, H. Yan, N. Papadopoulos, B. Vogelstein, K.W. Kinzler, V.E. Velculescu, The genetic landscape of the childhood cancer medulloblastoma, *Science* 331 (2011) 435–439.
- [43] T.J. Pugh, S.D. Weeraratne, T.C. Archer, D.A. Pomeranz Krummel, D. Auclair, J. Bochicchio, M.O. Carneiro, S.L. Carter, K. Cibulskis, R.L. Erlich, H. Greulich, M.S. Lawrence, N.J. Lennon, A. McKenna, J. Meldrum, A.H. Ramos, M.G. Ross, C. Russ, E. Shefler, A. Sivachenko, B. Sogoloff, P. Stojanov, P. Tamayo, J.P. Mesirov, V. Amani, N. Teider, S. Sengupta, J.P. Francois, P.A. Northcott, M.D. Taylor, F. Yu, G.R. Crabtree, A.G. Kautzmann, S.B. Gabriel, G. Getz, N. Jager, D.T. Jones, P. Lichter, S.M. Pfister, T.M. Roberts, M. Meyerson, S.L. Pomeroy, Y.J. Cho, Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations, *Nature* 488 (2012) 106–110.
- [44] R.D. Morin, M. Mendez-Lago, A.J. Mungall, R. Goya, K.L. Mungall, R.D. Corbett, N.A. Johnson, T.M. Severson, R. Chiu, M. Field, S. Jackman, M. Krzywinski, D.W. Scott, D.L. Trinh, J. Tamura-Wells, S. Li, M.R. Firme, S. Rogic, M. Griffith, S. Chan, O. Yakovenko, I.M. Meyer, E.Y. Zhao, D. Smailus, M. Mokska, S. Chittaranjan, L. Rimsza, A. Brooks-Wilson, J.J. Spinelli, S. Ben-Neriah, B. Meissner, B. Woolcock, M. Boyle, H. McDonald, A. Tam, Y. Zhao, A. Delaney, T. Zeng, K. Tse, Y. Butterfield, I. Birol, R. Holt, J. Schein, D.E. Horsman, R. Moore, S.J. Jones, J.M. Connors, M. Hirst, R.D. Gascoyne, M.A. Marra, Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma, *Nature* 476 (2011) 298–303.
- [45] L. Pasqualucci, V. Trifonov, G. Fabbri, J. Ma, D. Rossi, A. Chiarenza, V.A. Wells, A. Grunn, M. Messina, O. Elliot, J. Chan, G. Bhagat, A. Chadburn, G. Gaidano, C.G. Mullighan, R. Rabadan, R. Dalla-Favera, Analysis of the coding genome of diffuse large B-cell lymphoma, *Nat. Genet.* 43 (2011) 830–837.
- [46] E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, A. Jacobsen, C.J. Byrne, M.L. Heuer, E. Larsson, Y. Antipin, B. Reva, A.P. Goldberg, C. Sander, N. Schultz, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, *Cancer Discov.* 2 (2012) 401–404.
- [47] J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, Y. Sun, A. Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, N. Schultz, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, *Sci. Signal.* 6 (2013) pl1.
- [48] C. Chen, Y. Liu, A.R. Rappaport, T. Kitzing, N. Schultz, Z. Zhao, A.S. Shroff, R.A. Dickens, C.R. Vakoc, J.E. Bradner, W. Stock, M.M. LeBeau, K.M. Shannon, S. Kogan, J. Zuber, S.W. Lowe, MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia, *Cancer Cell* 25 (2014) 652–665.
- [49] K. Gala, Q. Li, A. Sinha, P. Razavi, M. Dorso, F. Sanchez-Vega, Y.R. Chung, R. Hendrickson, J.J. Hsieh, M. Berger, N. Schultz, A. Pastore, O. Abdel-Wahab, S. Chandralapaty, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERalpha enhancer function, *Oncogene* 37 (2018) 4692–4710.
- [50] Z. Zhang, J.R. Christin, C. Wang, K. Ge, M.H. Oktay, W. Guo, Mammary-stem-cell-based somatic mouse models reveal breast cancer drivers causing cell fate dysregulation, *Cell Rep.* 16 (2016) 3146–3156.
- [51] M. Compagno, W.K. Lim, A. Grunn, S.V. Nandula, M. Brahmachary, Q. Shen, F. Bertoni, M. Ponzoni, M. Scandurra, A. Califano, G. Bhagat, A. Chadburn, R. Dalla-Favera, L. Pasqualucci, Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma, *Nature* 459 (2009) 717–721.
- [52] O. Molavi, P. Wang, Z. Zak, P. Gelebart, A. Belch, R. Lai, Gene methylation and silencing of SOCS3 in mantle cell lymphoma, *Br. J. Haematol.* 161 (2013) 348–356.
- [53] K.J. Cheung, N.A. Johnson, J.G. Affleck, T. Severson, C. Steidl, S. Ben-Neriah, J. Schein, R.D. Morin, R. Moore, S.P. Shah, H. Qian, J.E. Paul, A. Telenius, T. Relander, W. Lam, K. Savage, J.M. Connors, C. Brown, M.A. Marra, R.D. Gascoyne, D.E. Horsman, Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis, *Cancer Res.* 70 (2010) 9166–9174.
- [54] C. Guo, L.H. Chen, Y. Huang, C.C. Chang, P. Wang, C.J. Pirozzi, X. Qin, X. Bao, P.K. Greer, R.E. McLendon, H. Yan, S.T. Keir, D.D. Bigner, Y. He, KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation, *Oncotarget* 4 (2013) 2144–2153.
- [55] A. Augert, Q. Zhang, B. Bates, M. Cui, X. Wang, G. Wildey, A. Dowlati, D. MacPherson, Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase kmt2d/MLL2: CALGB 151111 (alliance), *J. Thorac. Oncol.* 12 (2017) 704–713.
- [56] J. George, J.S. Lim, S.J. Jang, Y. Cun, L. Ozretic, G. Kong, F. Leenders, X. Lu, L. Fernandez-Cuesta, G. Bosco, C. Muller, I. Dahmen, N.S. Jahchan, K.S. Park, D. Yang, A.N. Karnezis, D. Vaka, A. Torres, M.S. Wang, J.O. Korbel, R. Menon, S.M. Chun, D. Kim, M. Wilkerson, N. Hayes, D. Engelmann, B. Putzer, M. Bos,

- S. Michels, I. Vlastic, D. Seidel, B. Pinther, P. Schaub, C. Becker, J. Altmüller, Y. Yokota, T. Kohno, R. Iwakawa, K. Tsuta, M. Noguchi, T. Muley, H. Hoffmann, P.A. Schnabel, I. Petersen, Y. Chen, A. Soltermann, V. Tischler, C.M. Choi, Y.H. Kim, P.P. Massion, Y. Zou, D. Jovanovic, M. Kontic, G.M. Wright, P.A. Russell, B. Solomon, I. Koch, M. Lindner, L.A. Muscarella, A. la Torre, J.K. Field, M. Jakopovic, J. Knezevic, E. Castanos-Velez, L. Roz, U. Pastorino, O.T. Brustugun, M. Lund-Iversen, E. Thunnissen, J. Kohler, M. Schuler, J. Botling, M. Sandelin, M. Sanchez-Cespedes, H.B. Salvesen, V. Achter, U. Lang, M. Bogus, P.M. Schneider, T. Zander, S. Ansen, M. Hallek, J. Wolf, M. Vingron, Y. Yatabe, W.D. Travis, P. Nurnberg, C. Reinhardt, S. Perner, L. Heukamp, R. Buttner, S.A. Haas, E. Brambilla, M. Peifer, J. Sage, R.K. Thomas, Comprehensive genomic profiles of small cell lung cancer, *Nature* 524 (2015) 47–53.
- [57] L. Jiang, J. Huang, B.W. Higgs, Z. Hu, Z. Xiao, X. Yao, S. Conley, H. Zhong, Z. Liu, P. Brohawn, D. Shen, S. Wu, X. Ge, Y. Jiang, Y. Zhao, Y. Lou, C. Morehouse, W. Zhu, Y. Sebastian, M. Czapiga, V. Oganessian, H. Fu, Y. Niu, W. Zhang, K. Streicher, D. Tice, H. Zhao, M. Zhu, L. Xu, R. Herbst, X. Su, Y. Gu, S. Li, L. Huang, J. Gu, B. Han, B. Jallal, H. Shen, Y. Yao, Genomic landscape survey identifies SRSF1 as a key oncogene in small cell lung cancer, *PLoS Genet.* 12 (2016) e1005895.
- [58] M. Simbolo, A. Mafficini, K.O. Sikora, M. Fassan, S. Barbi, V. Corbo, L. Mastracci, B. Rusev, F. Grillo, C. Vicentini, R. Ferrara, S. Pilotto, F. Davini, G. Pelosi, R.T. Lawlor, M. Chilosi, G. Tortora, E. Bria, G. Fontanini, M. Volante, A. Scarpa, Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D, *J. Pathol.* 241 (2017) 488–500.
- [59] J.S. Ross, K. Wang, O.R. Elkadi, A. Tarasen, L. Foulke, C.E. Sheehan, G.A. Otto, G. Palmer, R. Yelensky, D. Lipson, J. Chmielecki, S.M. Ali, J. Elvin, D. Morosini, V.A. Miller, P.J. Stephens, Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer, *J. Clin. Pathol.* 67 (2014) 772–776.
- [60] A. Dowlati, M.B. Lipka, K. McColl, S. Dabir, M. Behtaj, A. Kresak, A. Miron, M. Yang, N. Sharma, P. Fu, G. Wildey, Clinical correlation of extensive-stage small-cell lung cancer genomics, *Ann. Oncol.* 27 (2016) 642–647.
- [61] S. Umemura, S. Mimaki, H. Makinoshima, S. Tada, G. Ishii, H. Ohmatsu, S. Niho, K. Yoh, S. Matsumoto, A. Takahashi, M. Morise, Y. Nakamura, A. Ochiai, K. Nagai, R. Iwakawa, T. Kohno, J. Yokota, Y. Ohe, H. Esumi, K. Tsuchihara, K. Goto, Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis, *J. Thorac. Oncol.* 9 (2014) 1324–1331.
- [62] E.J. Jordan, H.R. Kim, M.E. Arcila, D. Barron, D. Chakravarty, J. Gao, M.T. Chang, A. Ni, R. Kundra, P. Jonsson, G. Jayakumaran, S.P. Gao, H.C. Johnsen, A.J. Hanrahan, A. Zehir, N. Rekhtman, M.S. Ginsberg, B.T. Li, H.A. Yu, P.K. Paik, A. Drilon, M.D. Hellmann, D.N. Reales, R. Benayed, V.W. Rusch, M.G. Kris, J.E. Chaff, J. Baselga, B.S. Taylor, N. Schultz, C.M. Rudin, D.M. Hyman, M.F. Berger, D.B. Solit, M. Ladanyi, G.J. Riely, Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies, *Cancer Discov.* 7 (2017) 596–609.
- [63] L. Ding, G. Getz, D.A. Wheeler, E.R. Mardis, M.D. McLellan, K. Cibulskis, C. Sougnez, H. Greulich, D.M. Muzny, M.B. Morgan, L. Fulton, R.S. Fulton, Q. Zhang, M.C. Wendt, M.S. Lawrence, D.E. Larson, K. Chen, D.J. Dooling, A. Sabo, A.C. Hawes, H. Shen, S.N. Jhangiani, L.R. Lewis, O. Hall, Y. Zhu, T. Mathew, Y. Ren, J. Yao, S.E. Scherer, K. Clerc, G.A. Metcalf, B. Ng, A. Milosavljevic, M.L. Gonzalez-Garay, J.R. Osborne, R. Meyer, X. Shi, Y. Tang, D.C. Koboldt, L. Lin, R. Abbott, T.L. Miner, C. Pohl, G. Fewell, C. Haipek, H. Schmidt, B.H. Dunford-Shore, A. Kraja, S.D. Crosby, C.S. Sawyers, T. Vickery, S. Sander, J. Robinson, W. Winckler, J. Baldwin, L.R. Chiriac, A. Dutt, T. Fennell, M. Hanna, B.E. Johnson, R.C. Onofrio, R.K. Thomas, G. Tonon, B.A. Weir, X. Zhao, L. Ziaugra, M.C. Zody, T. Giordano, M.B. Orringer, J.A. Roth, M.R. Spitz, Wistuba II, B. Ozenberger, P.J. Good, A.C. Chang, D.G. Beer, M.A. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W.D. Travis, W. Pao, M.A. Province, G.M. Weinstein, H.E. Varmus, S.B. Gabriel, E.S. Lander, R.A. Gibbs, M. Meyerson, R.K. Wilson, Somatic mutations affect key pathways in lung adenocarcinoma, *Nature* 455 (2008) 1069–1075.
- [64] N.A. Rizvi, M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, W. Lee, J. Yuan, P. Wong, T.S. Ho, M.L. Miller, N. Rekhtman, A.L. Moreira, F. Ibrahim, C. Bruggeman, B. Gasm, R. Zappasodi, Y. Maeda, C. Sander, E.B. Garon, T. Merghoub, J.D. Wolchok, T.N. Schumacher, T.A. Chan, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, *Science* 348 (2015) 124–128.
- [65] J.D. Campbell, A. Alexandrov, J. Kim, J. Wala, A.H. Berger, C.S. Peadarallu, S.A. Shukla, G. Guo, A.N. Brooks, B.A. Murray, M. Imielinski, X. Hu, S. Ling, R. Akbani, M. Rosenberg, C. Cibulskis, A. Ramachandran, E.A. Collisson, D.J. Kwiatkowski, M.S. Lawrence, J.N. Weinstein, R.G. Verhaak, C.J. Wu, P.S. Hammerman, A.D. Cherniack, G. Getz, N. Cancer Genome Atlas Research, M.N. Artyomov, R. Schreiber, R. Govindan, M. Meyerson, Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas, *Nat. Genet.* 48 (2016) 607–616.
- [66] T. Vavala, V. Monica, M. Lo Iacono, T. Mele, S. Busso, L. Righi, M. Papotti, G.V. Scagliotti, S. Novello, Precision medicine in age-specific non-small-cell-lung-cancer patients: integrating biomolecular results into clinical practice—A new approach to improve personalized translational research, *Lung Cancer* 107 (2017) 84–90.
- [67] M. Imielinski, A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, E. Hodis, J. Cho, J. Suh, M. Capelletti, A. Sivachenko, C. Sougnez, D. Auclair, M.S. Lawrence, P. Stojanov, K. Cibulskis, K. Choi, L. de Waal, T. Sharifnia, A. Brooks, H. Greulich, S. Banerji, T. Zander, D. Seidel, F. Leenders, S. Ansen, C. Ludwig, W. Engel-Riedel, E. Stoelben, J. Wolf, C. Goparaju, K. Thompson, W. Winckler, D. Kwiatkowski, B.E. Johnson, P.A. Janne, V.A. Miller, W. Pao, W.D. Travis, H.I. Pass, S.B. Gabriel, E.S. Lander, R.K. Thomas, L.A. Garraway, G. Getz, M. Meyerson, Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing, *Cell* 150 (2012) 1107–1120.
- [68] S. Yin, J. Yang, B. Lin, W. Deng, Y. Zhang, X. Yi, Y. Shi, Y. Tao, J. Cai, C.I. Wu, G. Zhao, L.D. Hurst, J. Zhang, L. Hu, X. Kong, Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients, *Sci. Rep.* 4 (2014) 6036.
- [69] M. Choi, H. Kadara, J. Zhang, E.R. Parra, J. Rodriguez-Canales, S.G. Gaffney, Z. Zhao, C. Behrens, J. Fujimoto, C. Chow, K. Kim, N. Kalhor, C. Moran, D. Rimm, S. Swisher, D.L. Gibbons, J. Heymach, E. Kaftan, J.P. Townsend, T.J. Lynch, J. Schlessinger, J. Lee, R.P. Lifton, R.S. Herbst, Wistuba II, Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function, *Ann. Oncol.* 28 (2017) 83–89.
- [70] W. Xiong, Z. Deng, Y. Tang, Z. Deng, M. J. Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer, *Biochem. Biophys. Res. Commun.* 504 (2018) 129–136.
- [71] A. Abudurehman, J. Ainiwaer, Z. Hou, M. Niyaz, A. Turghun, A. Hasim, H. Zhang, X. Lu, I. Sheyhidin, High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma, *J. Cancer Res. Clin. Oncol.* 144 (2018) 1025–1035.
- [72] S. Lv, L. Ji, B. Chen, S. Liu, C. Lei, X. Liu, X. Qi, Y. Wang, E. Lai-Han Leung, H. Wang, L. Zhang, X. Yu, Z. Liu, Q. Wei, L. Lu, Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4, *Oncogene* 37 (2018) 1354–1368.
- [73] S.J. Cho, C. Yoon, J.H. Lee, K.K. Chang, J.X. Lin, Y.H. Kim, M.C. Kook, B.A. Aksoy, D.J. Park, K.H. Tomaszowski, D.T. Smoot, N. Schultz, S.S. Yoon, KMT2C mutations in diffuse-type gastric adenocarcinoma promote epithelial-to-mesenchymal transition, *Clin. Cancer Res.* 24 (2018) 6556–6569.
- [74] H. Rahnamoun, J. Hong, Z. Sun, J. Lee, H. Lu, S.M. Lauberth, Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4, *J. Biol. Chem.* 293 (2018) 13234–13246.
- [75] S. Roy, K.H. Tomaszowski, J.W. Luzwick, S. Park, J. Li, M. Murphy, K. Schlacher, p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLtheta pathways, *Elife* 7 (2018).
- [76] D.H. Kim, J. Kim, J.W. Lee, Requirement for MLL3 in p53 regulation of hepatic expression of small heterodimer partner and bile acid homeostasis, *Mol. Endocrinol.* 25 (2011) 2076–2083.
- [77] J. Lee, D.H. Kim, S. Lee, Q.H. Yang, D.K. Lee, S.K. Lee, R.G. Roeder, J.W. Lee, A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4, *Proc. Natl. Acad. Sci. U. S. A.* 106 (2009) 8513–8518.
- [78] J. Zhu, M.A. Sammons, G. Donahue, Z. Dou, M. Vedadi, M. Getlik, D. Barsyte-Lovejoy, R. Al-awar, B.W. Katona, A. Shilatfard, J. Huang, X. Hua, C.H. Arrowsmith, S.L. Berger, Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth, *Nature* 525 (2015) 206–211.
- [79] C. Guo, C.C. Chang, M. Wortham, L.H. Chen, D.N. Kernagis, X. Qin, Y.W. Cho, J.T. Chi, G.A. Grant, R.E. McLendon, H. Yan, K. Ge, N. Papadopoulos, D.D. Bigner, Y. He, Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways, *Proc. Natl. Acad. Sci. U. S. A.* 109 (2012) 17603–17608.
- [80] I. MacFawn, H. Wilson, L.A. Selth, I. Leighton, I. Serebriiskii, R.C. Bleackley, O. Elzamazzy, J. Farris, P.M. Pifer, J. Richer, S.M. Frisch, Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers, *Mol. Immunol.* 105 (2018) 137–149.
- [81] J.E. Lee, C. Wang, S. Xu, Y.W. Cho, L. Wang, X. Feng, A. Baldrige, V. Sartorelli, L. Zhuang, W. Peng, K. Ge, H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation, *Elife* 2 (2013) e01503.
- [82] M. Mohan, H.M. Herz, A. Shilatfard, SnapShot: histone lysine methylase complexes, *Cell* 149 (2012) 498–498 e491.
- [83] E. Toska, P. Castel, S. Chhangawala, A. Arruabarrena-Aristorena, C. Chan, V.C. Hristidis, E. Cocco, M. Sallaku, G. Xu, J. Park, G. Minuesa, S.G. Shifman, N.D. Socci, R. Koche, C.S. Leslie, M. Scaltriti, J. Baselga, PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression, *Cell Rep.* 27 (2019) 294–306 e295.
- [84] E. Toska, H.U. Osmanbeyoglu, P. Castel, C. Chan, R.C. Hendrickson, M. Elkabets, M.N. Dickler, M. Scaltriti, C.S. Leslie, S.A. Armstrong, J. Baselga, PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D, *Science* 355 (2017) 1324–1330.
- [85] A. Bosch, Z. Li, A. Bergamaschi, H. Ellis, E. Toska, A. Prat, J.J. Tao, D.E. Spratt, N.T. Viola-Villegas, P. Castel, G. Minuesa, N. Morse, J. Rodon, Y. Ibrahim, J. Cortes, J. Perez-Garcia, P. Galvan, J. Grueso, M. Guzman, J.A. Katzenellenbogen, M. Kharas, J.S. Lewis, M. Dickler, V. Serra, N. Rosen, S. Chandralapaty, M. Scaltriti, J. Baselga, PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer, *Sci. Transl. Med.* 7 (2015) 283ra251.
- [86] B.D. Yu, J.L. Hess, S.E. Horning, G.A. Brown, S.J. Korsmeyer, Altered Hox expression and segmental identity in *MLL*-mutant mice, *Nature* 378 (1995) 505–508.
- [87] P. Aytton, S.F. Sneddon, D.B. Palmer, I.R. Rosewell, M.J. Owen, B. Young, R. Presley, V. Subramanian, Truncation of the MLL Gene in Exon 5 by Gene Targeting Leads to Early Preimplantation Lethality of Homozygous Embryos vol. 30, (2001), pp. 201–212.
- [88] S. Glaser, J. Schaft, S. Lubitz, K. Vintersten, F. van der Hoeven, K.R. Tufteland, R. Aasland, K. Anastasiadis, S.L. Ang, A.F. Stewart, Multiple epigenetic maintenance factors implicated by the loss of MLL2 in mouse development,

- Development 133 (2006) 1423–1432.
- [89] K. Aoshima, E. Inoue, H. Sawa, Y. Okada, Paternal H3K4 methylation is required for minor zygotic gene activation and early mouse embryonic development, *EMBO Rep.* 16 (2015) 803–812.
- [90] S.P. Strom, R. Lozano, H. Lee, N. Dorrani, J. Mann, P.F. O'Laigue, N. Mans, J.L. Deignan, E. Vilain, S.F. Nelson, W.W. Grody, F. Quintero-Rivera, De Novo variants in the KMT2A (MLL) gene causing atypical Wiedemann-Steiner syndrome in two unrelated individuals identified by clinical exome sequencing, *BMC Med. Genet.* 15 (2014) 49.
- [91] W.D. Jones, D. Dafou, M. McEntagart, W.J. Woollard, F.V. Elmslie, M. Holder-Espinasse, M. Irving, A.K. Sagar, S. Smithson, R.C. Trembath, C. Deshpande, M.A. Simpson, De novo mutations in MLL cause Wiedemann-Steiner syndrome, *Am. J. Hum. Genet.* 91 (2012) 358–364.
- [92] H. Zhang, B. Xiang, H. Chen, X. Chen, T. Cai, A novel deletion mutation in KMT2A identified in a child with ID/DD and blood eosinophilia, *BMC Med. Genet.* 20 (2019) 38.
- [93] M. Zech, S. Boesch, E.M. Maier, I. Borggraefe, K. Vill, F. Laccone, V. Pilshofer, A. Ceballos-Baumann, B. Alhaddad, R. Berutti, W. Poewe, T.B. Haack, B. Haslinger, T.M. Strom, J. Winkelmann, Haploinsufficiency of KMT2B, encoding the lysine-specific histone methyltransferase 2B, results in early-onset generalized dystonia, *Am. J. Hum. Genet.* 99 (2016) 1377–1387.
- [94] K.M. Gorman, E. Meyer, M.A. Kurian, Review of the phenotype of early-onset generalised progressive dystonia due to mutations in KMT2B, *Eur. J. Paediatr. Neurol.* 22 (2018) 245–256.
- [95] T. Kleefstra, J.M. Kramer, K. Neveling, M.H. Willemsen, T.S. Koemans, L.E. Vissers, W. Wissink-Lindhout, M. Fenckova, W.M. van den Akker, N.N. Kasri, W.M. Nillesen, T. Prescott, R.D. Clark, K. Devriendt, J. van Reeuwijk, A.P. de Brouwer, C. Gilissen, H. Zhou, H.G. Brunner, J.A. Veltman, A. Schenck, H. van Bokhoven, Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability, *Am. J. Hum. Genet.* 91 (2012) 73–82.
- [96] T.S. Koemans, T. Kleefstra, M.C. Chubak, M.H. Stone, M.R.F. Reijnders, S. de Munnik, M.H. Willemsen, M. Fenckova, C. Stumpel, L.A. Bok, M. Sifuentes Saenz, K.A. Byerly, L.B. Baughn, A.P.A. Stegmann, R. Pfundt, H. Zhou, H. van Bokhoven, A. Schenck, J.M. Kramer, Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder, *PLoS Genet.* 13 (2017) e1006864.
- [97] C. Lintas, A.M. Persico, Unraveling molecular pathways shared by Kabuki and Kabuki-like syndromes, *Clin. Genet.* 94 (2018) 283–295.
- [98] H. Teranishi, Y. Koga, K. Nakashima, E. Morihana, K. Ishii, Y. Sakai, T. Taguchi, Y. Oda, N. Miyake, N. Matsumoto, S. Ohga, Cancer management in Kabuki syndrome: the first case of Wilms tumor and a literature review, *J. Pediatr. Hematol. Oncol.* 40 (2018) 391–394.
- [99] S.S. Dhar, D. Zhao, T. Lin, B. Gu, K. Pal, S.J. Wu, H. Alam, J. Lv, K. Yun, V. Gopalakrishnan, E.R. Flores, P.A. Northcott, V. Rajaram, W. Li, A. Shilatifard, R.V. Sillitoe, K. Chen, M.G. Lee, MLL4 is required to maintain broad H3K4me3 peaks and super-enhancers at tumor suppressor genes, *Mol. Cell* 70 (2018) 825–841 e826.
- [100] A.P. Feinberg, R. Ohlsson, S. Henikoff, The epigenetic progenitor origin of human cancer, *Nat. Rev. Genet.* 7 (2006) 21–33.
- [101] A.P. Feinberg, M.A. Koldobskiy, A. Gondor, Epigenetic modulators, modifiers and mediators in cancer aetiology and progression, *Nat. Rev. Genet.* 17 (2016) 284–299.
- [102] T. Rampias, D. Karagiannis, M. Avgeris, A. Polyzos, A. Kokkalis, Z. Kanaki, E. Kousidou, M. Tzetzis, E. Kanavakis, K. Stravodimos, K.N. Manola, G.E. Pantelias, A. Scorilas, A. Klinakis, The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer, *EMBO Rep.* 20 (2019).
- [103] G. Senisterra, H. Wu, A. Allali-Hassani, G.A. Wasney, D. Barsyte-Lovejoy, L. Dombrovski, A. Dong, K.T. Nguyen, D. Smil, Y. Bolshan, T. Hajian, H. He, A. Seitova, I. Chau, F. Li, G. Poda, J.F. Couture, P.J. Brown, R. Al-Awar, M. Schapira, C.H. Arrowsmith, M. Vedadi, Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5, *Biochem. J.* 449 (2013) 151–159.
- [104] I.C. Tsai, K. McKnight, S.U. McKinstry, A.T. Maynard, P.L. Tan, C. Golzio, C.T. White, D.J. Price, E.E. Davis, H. Amrine-Madsen, N. Katsanis, Small molecule inhibition of RAS/MAPK signaling ameliorates developmental pathologies of Kabuki Syndrome, *Sci. Rep.* 8 (2018) 10779.